1. Value in Health Regional Issues
Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia 
Didik Setiawan, MSc, Apt, Franklin Christiaan Dolk, MSc, Auliya A. Suwantika, PhD, Tjalke Arend Westra, PhD, Jan C. WIlschut, PhD, Maarten Jacobus Postma, PhD 
Value in Health Regional Issues 
Volume 9, Pages (May 2016)
DOI: /j.vhri
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1 Markov model for the development of cervical cancer.
Value in Health Regional Issues 2016 9, 84-92DOI: ( /j.vhri )
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Estimated annual cases of cervical cancer prevented (A) and life-years saved (B) by VIA screening, or VIA screening in combination with HPV vaccination. HPV, human papillomavirus; VIA, visual inspection with acetic acid.
Value in Health Regional Issues 2016 9, 84-92DOI: ( /j.vhri )
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
The effect of market vaccine price on ICER in terms of booster dose is needed (black square) and not needed (gray square) to achieve lifelong protection. ICER, incremental cost-effectiveness ratio; I$, international dollar.
Value in Health Regional Issues 2016 9, 84-92DOI: ( /j.vhri )
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
Cost-effectiveness acceptability curve, specifically 1 to 3 times the gross domestic product per capita is indicated with the corresponding probability to be cost-effective. HPV, human papillomavirus; I$, international dollar; QALY, quality-adjusted life-year; VIA, visual inspection with acetic acid.
Value in Health Regional Issues 2016 9, 84-92DOI: ( /j.vhri )
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

6. Fig. 5
Univariate sensitivity analyses for VIA screening alone (A) and VIA screening combined with vaccination (B) compared with no intervention. CC, cervical cancer; QALY, quality-adjusted life-year; VIA, visual inspection with acetic acid.
Value in Health Regional Issues 2016 9, 84-92DOI: ( /j.vhri )
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions